Studies Of Metronomic Chemotherapy And Bevacizumab For The Nude Mice Model Of Human Hepatocellular Carcinoma

PurposeTo investigate the role of metronomic chemotherapy and Bevacizumab for hepatocellular carcinoma in nude mice model. MethodsNude mice bearing orthotopic xenografty highly metastatic human HCC(LCI-D20) were treated with Bevacizumab, Gefitinib, Bevacizumab and Gefitinib, metronomic dosage S-1. Tumor quality was measured and microvessel density(MVD) was used to evaluate angiogenesis in tumor. ResultsBevacizumab, Gefitinib, Bevacizumab and Gefitinib, metronomic dosage S-l reduced MVD of tumor and tumor quality. ConclusionBevacizumab, Gefitinib, Bevacizumab and Gefitinib, metronomic dosage S-l has a role on anti-angiogenesis of hepatocellular carcinoma.